1. Home
  2. PTGX vs CRL Comparison

PTGX vs CRL Comparison

Compare PTGX & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

N/A

Current Price

$143.78

Market Cap

9.3B

Sector

Health Care

ML Signal

N/A

Logo Charles River Laboratories International Inc.

CRL

Charles River Laboratories International Inc.

HOLD

Current Price

$273.31

Market Cap

10.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTGX
CRL
Founded
2006
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3B
10.8B
IPO Year
2016
1999

Fundamental Metrics

Financial Performance
Metric
PTGX
CRL
Price
$143.78
$273.31
Analyst Decision
Strong Buy
Buy
Analyst Count
13
12
Target Price
$108.23
$198.27
AVG Volume (30 Days)
456.7K
768.9K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.35
N/A
Revenue
N/A
$1,857,601,000.00
Revenue This Year
$874.25
N/A
Revenue Next Year
N/A
$3.04
P/E Ratio
$63.06
N/A
Revenue Growth
N/A
10.48
52 Week Low
$57.90
$144.26
52 Week High
$160.81
$303.31

Technical Indicators

Market Signals
Indicator
PTGX
CRL
Relative Strength Index (RSI) 52.79 47.29
Support Level $141.95 $215.89
Resistance Level $160.81 $303.31
Average True Range (ATR) 5.37 7.37
MACD -0.89 -4.37
Stochastic Oscillator 36.38 16.21

Price Performance

Historical Comparison
PTGX
CRL

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

About CRL Charles River Laboratories International Inc.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Share on Social Networks: